Paris, July 11, 2011 – BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated
to specialty and orphan oncology products, today announces the grant of a European patent
protecting its Transdrug™ nanotechnology. This new industrial property notably covers
Livatag®, the first product of its « Orphan oncology products » portfolio until 2023.
A phase III clinical trial application for Livatag® in primary liver cancer has been submitted on
June 27, 2011. This treatment based on the Transdrug™ nanoparticles delivery system
delivers doxorubicin into the resistant tumor cell, overcoming multi-drug resistance
mechanisms. These mechanisms are very frequent in some cancers, occurring either
spontaneously or following a first treatment. The primary liver cancer, third leading cause of
death by cancer worldwide, is spontaneously chemo resistant.
“Livatag® is already protected until 2019 by a first family of worldwide granted patents
covering the Transdrug™ technology. The grant of this second European patent
considerably strengthens the industrial property of Livatag® and completes the market
exclusivity given by the orphan status, thus reinforcing the value of this key asset for the
Company”, comments Judith Greciet, CEO of BioAlliance Pharma.
About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan
products –– BioAlliance conceives and develops innovative products, for specialty markets especially
in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition
is to become a leading player in these fields by coupling innovation to patient needs. The company’s
teams have the key competencies required to identify, develop and register drugs in Europe and the
USA; the products’ commercialization rights are licensed to international commercial partners invested
in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches
help overcome drug resistance and improve patient health & quality of life.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU US, Korea)
Sitavir® (Acyclovir Lauriad TM) (labialis herpes): Positive phase III final results; registration status
Fentanyl LauriadTM (chronic cancer pain): Positive preliminary Phase I results
Orphan Oncology products
Livatag® (Doxorubicin Transdrug™) in primary) liver cancer: Phase II results on survival
Clonidine LauriadTM (mucositis): Phase II on going
AMEP® (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2010 Reference Document filed with the AMF on April 7, 2011, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA
Judith Greciet, CEO
Tel +33 1 45 58 70 61
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
Tel.: +33 6 64 18 99 59